Indaptus Therapeutics, Inc.
INDPHealthcareNASDAQBiotechnology · Last scanned Jun 2, 2026
Scan Results
Daily timeframeIndaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. With a market capitalization of $217.4M, it sits in micro-cap territory. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Market Cap
$217.4M
Beta
1.39
P/E (TTM)
—
P/E (Fwd)
-1.38
EPS (TTM)
$-12.70
EPS (Fwd)
$-1.39
ROE
-931.8%
ROA
-286.8%
Cash
$1.5M
Total Debt
$0
Free CF
-$10.8M
52W Change
-80.3%
Annual Financials
Cash vs Debt
Indaptus Therapeutics, Inc. reports $1.5M in cash and $0 in total debt. Free cash flow is running at -$10.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -931.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing INDP.